About this episode
Photobiomodulation (PBM) and low-level light therapy (LLLT) are everywhere, and so are the claims: more ATP, better recovery, fat loss, nervous system balance, strength gains… all from the same “red light” buzzword.
In this 3-paper masterclass, Dr. Mike Belkowski breaks the hype down into evidence, endpoints, and bottlenecks. You’ll get a clean, practical analysis of three very different PBM applications:
Body circumference reduction (systematic review of sham-controlled RCTs)
Autonomic nervous system regulation using HRV after infra-auricular/vagus-region PBM (randomized controlled trial)
Upper-body performance on a real-world compound lift (bench press) in collegiate athletes (double-blind repeated-measures)
Then we connect the dots: why PBM can show a strong signal in one domain, a weak signal in another, and no signal at all when the limiting factor isn’t mitochondrial energy; but coordination, sleep, stress, or recovery terrain.
Bottom line: light is real, but its application is not universal — it works when the tool matches the job.
(Educational content only, not medical advice.)
-
Articles Discussed in Episode:
The influence of photobiomodulation on upper body muscular performance in collegiate athletes
Effects of Acute Photobiomodulation on Heart Rate Variability in Physically Active Individuals: A Randomized and Controlled Clinical Trial
Low-level laser therapy for reducing body circumferences: a systematic review
-
Key Quotes From Dr. Mike:
“The PBM trap is thinking ‘more ATP’ automatically means better everything.”
“Light therapy is real, but real does not mean universal. It means context-dependent.”
“HRV is a moving target — sleep, caffeine, hydration, stress can drown out small effects.”
“If you want nervous system balance, the big levers are still sleep, rhythm, breath, and training load.”
“Ask better questions: what tissue, what depth, what dose, what endpoint?”
-
Key points
PBM is a signal, not a guarantee ? Match the tool to the job.
Paper 1 (LLLT body contouring): short-term circumference reductions beat sham; high satisfaction; good tolerability; only 3 RCTs ? promising but early.
Devices/wavele
